Now researchers from GlaxoSmithKline report studies showing that regular use of inhaled steroids seem to cut COPD death and hospitalization by 30%. GlaxoSmithKline is a WebMD sponsor.
The results "indicate a beneficial association of inhaled corticosteroids and the risk of death or rehospitalization in COPD," report GlaxoSmithKline's Victor A. Kiri, PhD, and colleagues.
The findings appear in the Aug. 15 issue of the American Journal of Respiratory and Critical Care Medicine.
2 Studies, 1 Result
Kiri's team used data collected by doctors in the U.K. They compared 393 COPD patients treated with inhaled steroids to 393 matched COPD patients who did not get the treatment. The treated patients had 31% fewer deaths and hospitalizations.
The researchers then analyzed 2,222 cases of COPD. They found that those treated with inhaled steroids had 29% fewer deaths and hospitalizations.
The findings do not prove that inhaled steroids help people with COPD, notes Johns Hopkins researcher Jonathan M. Samet, MD, in an editorial accompanying the Kiri report.
"Reflecting the still incomplete and evolving evidence base, some recent recommendations on the use of inhaled steroids in COPD have been guarded," Samet writes. "The new report by Kiri and co-workers suggests a 30% reduction in risk for rehospitalization or death -- a meaningful gain for COPD."
Samet suggests that more definitive proof will come from an ongoing clinical trial with 6,000 COPD patients.